PAVmed Inc. (OTCMKTS:PAVM) stock went down marginally in the opening session on Wednesday. After a steep rise in February, the stock has been moving in a range and waiting for the next direction. The stock has more than doubled since the beginning of this year.
As of 10:18, PAVM stock has moved down by 0.30% at $4.73. The stock has traded 618K shares, below its average volume of 3.72 shares. The stock opened at $4.78 and moved in a range of $4.6350 – 4.8600.
PAVmed Subsidiary Lucid Diagnostics Receives CE Mark Certification for its EsoCheck® Esophageal Cell Collection Device
- announced that Lucid’s EsoCheck® Esophageal Cell Collection Device with Collect+Protect™ technology (“EsoCheck”) has received CE Mark certification.
- EU-based Notified Body TÜV Rhineland LGA Products GMBH issued a CE Certificate, effective May 24, 2021, declaring that EsoCheck conforms to the essential requirements of Medical Device Directive 93/42/EEC. With CE Mark secured, EsoCheck may now be marketed in CE Mark European countries, which include the European Economic Area (the EU, Norway, Iceland, and Lichtenstein), Switzerland, and, until July 1, 2023, the United Kingdom.
- EsoCheck is an FDA-cleared swallowable balloon capsule catheter, which allows a clinician to sample surface cells from the esophagus in a less than 5-minute non-invasive office procedure, the only such device capable of doing so in an anatomically targeted fashion, without sample dilution or contamination (EsoCheck animation).